Current therapy strategies for neuroblastoma

被引:0
|
作者
Ladenstein, R. [1 ]
机构
[1] St Anna Kinderkrebsforsch eV, A-1090 Vienna, Austria
关键词
Neuroblastoma; Risk-adapted treatment concept; Chromosome aberrations; MYCN protein; human; Gene amplification; RISK; CLASSIFICATION; ANTIBODY; SYSTEM;
D O I
10.1007/s00112-012-2690-9
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Neuroblastoma is the most common form of extracranial solid tumor in childhood. Depending on the localization neuroblastomas result in characteristic but site-dependent symptoms. An iodine-123-meta-iodobenzylguanidine (MIBG) scan is the standard diagnostic procedure of choice for all tumor localizations. Bilateral marrow aspirates from the posterior iliac crest and biopsies of bone marrow are also indispensible. The decisive marker for assessment of dignity of neuroblastomas is MYCN oncogene amplification. Neuroblastomas must be treated in a risk-adapted manner. For this reason exact diagnostics and classification are indispensible and the therapy should be carried out in specialized centers within the framework of quality assured therapy optimization studies.
引用
收藏
页码:947 / +
页数:9
相关论文
共 50 条
  • [1] Aktuelle Therapiestrategien beim NeuroblastomCurrent therapy strategies for neuroblastoma
    R. Ladenstein
    Monatsschrift Kinderheilkunde, 2012, 160 : 947 - 957
  • [2] Current and Future Strategies for Relapsed Neuroblastoma: Challenges on the Road to Precision Therapy
    Morgenstern, Daniel A.
    Baruchel, Sylvain
    Irwin, Meredith S.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2013, 35 (05) : 337 - 347
  • [3] Neuroblastoma in infancy: Current diagnosis and therapy
    Humpl, T
    Gutjahr, P
    AKTUELLE UROLOGIE, 1996, 27 (04) : 200 - 204
  • [4] Therapy resistance in neuroblastoma: Mechanisms and reversal strategies
    Zhou, Xia
    Wang, Xiaokang
    Li, Nan
    Guo, Yu
    Yang, Xiaolin
    Lei, Yuhe
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [5] Exosomes: Novel Players of Therapy Resistance in Neuroblastoma
    Richard, Heather
    Pokhrel, Arya
    Chava, Srinivas
    Pathania, Anup
    Katta, Santharam S.
    Challagundla, Kishore B.
    TUMOR MICROENVIRONMENT: MOLECULAR PLAYERS, PT B, 2020, 1277 : 75 - 85
  • [6] Towards a turning point of neuroblastoma therapy
    Tonini, Gian Paolo
    Nakagawara, Akira
    Berthold, Frank
    CANCER LETTERS, 2012, 326 (02) : 128 - 134
  • [7] Dinutuximab for maintenance therapy in pediatric neuroblastoma
    McGinty, Lauren
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (08) : 563 - 567
  • [8] 131I MIBG therapy in neuroblastoma:: Mechanisms, rationale, and current status
    Tepmongkol, S
    Heyman, S
    MEDICAL AND PEDIATRIC ONCOLOGY, 1999, 32 (06): : 427 - 431
  • [9] CLINICAL STRATEGIES FOR THE TREATMENT OF NEUROBLASTOMA
    NIETHAMMER, D
    HANDGRETINGER, R
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (04) : 568 - 571
  • [10] Current aspects of biology, risk assessment, and treatment of neuroblastoma
    Haase, GM
    Perez, C
    Atkinson, JB
    SEMINARS IN SURGICAL ONCOLOGY, 1999, 16 (02): : 91 - 104